ProMIS Neurosciences Inc PMN

FDA decision will have waterfall effect on other companies

[retiredcop]

https://www.barrons.com/articles/fda-biogen-decision-biotech-stocks-51622553280

[DavidKingCanada]

I believe all companies related will have some sort of fallback or possibly an increase in SP if and when Aducanumab is approved by the FDA. Hoping for the best!

[M101]

Hey DavidKing, are the one giving a thumbs-up for almost every post? It started when you arrived and you're the only one not getting them.

[DavidKingCanada]

When we see a post that is relevant and has a positive aspect to it, we will definitely provide an upvote. We can always skip over your name ;) Cheers mate!

[M101]

I have no problem with it, we're all in the entertainment business here

[DavidKingCanada]

We enjoyed your previous post about Epstein and Prostitutes. It was quite entertaining and gave us quite the chuckle! 

[Annayya]

What do you think will be the effect on PMN. There are numerous articles comparing PMN to Biogen. Could PMN share price double with our best in class approach? I am hoping that the approval news comes before June 7th, preferably on June 4th. I don't like the suspense on a Monday morning and want to get it over with this week.

[DavidKingCanada]

Am also curious as to what RC as to say, hoping for Great News!

[retiredcop]

So far what I have been hearing as speculation on share price for PMN... I think if its a approval for Biogen up we are up 2-5 cents ... if its a non approval for biogen its 3-5 cents in the opposite direction. I think we already see that regardless of what happens to Biogen, the new investors have indicated they are taking pmn310 to clinicals and I would expect that there will be a third party

[BottomBroker]

Do you have any links to these articles that compare PMN and Biogen? 

[Annayya]

Here's an example https://stockdaymedia.com/promis-neurosciences-alzheimers-disease-program-takes-on-renewed-significance-following-positive-aducanumab-news/ I have been following this stock for years and there's so many times they compared PMN310 to being a better alternative to aducanumab. I think a quick google search will find most of the articles. 

[M101]

Ouch! Paid content from Promis doesn't count as an article.  This scenario was so completely contrived by our consultants. These bozos could have gone the opposite direction by forecasting Aducanumab's failure and then we'd be in a win-win situation regardless of the FDA panel review.  They chose instead to put our money into an excuse for their promotional failures, and now

[Annayya]

Is this scientific report considered a paid article too? Again just a quick google search, there's more out there. Whether you like it or not PMN310 clinical investment will progress much faster if aducanumab is approved even with lots of conditions. We can't undo all the comparisons done in the past, so now we have to hope that aducanumab gets approved. The Biogen approval will create

[retiredcop]

This is my view of this whole situation...Regardless of whether Biogen gets approval.or not...pmn is going to be focusing on the comments that the fda makes....we know regardless of the decision... the fda will be expressing concerns that pmn is going to target when they roll.out the things that they feel.pmn310 can do. .what better way to gain approval with the regulators and their peers then to

[BottomBroker]

Umm, yeah, as M101 pointed out, those "articles" are produced by PMN. PMN is comparing Biogen to themselves. 

[Mole101]

  In a note out Wednesday, UBS analyst Colin Bristow wrote that a former FDA official he didn’t identify told him he sees a 60% chance of the agency approving aducanumab. “Given we are less than one week away from the [FDA deadline], our expert now sees a 60% prob of approval (vs. 30% in April), noting that FDA is likely taking time to finalize the label/post marketing requirements